Asciminib
Asciminib
Asciminib (pronounced as-see-min-ib) is a type of medication used in the treatment of chronic myeloid leukemia (CML). It is classified as a tyrosine kinase inhibitor (TKI), specifically a myristoyl pocket binder.
Etymology
The name "Asciminib" is derived from the pharmaceutical company that developed it, Novartis, and the class of drugs it belongs to, tyrosine kinase inhibitors. The "-ib" suffix is common in the names of TKIs.
Usage
Asciminib is used to treat chronic myeloid leukemia, a type of cancer that affects the white blood cells. It is particularly used in cases where other treatments have failed or are not suitable. Asciminib works by blocking the action of a protein called BCR-ABL, which is responsible for the growth of cancer cells.
Related Terms
- Chronic myeloid leukemia: A type of cancer that starts in certain blood-forming cells of the bone marrow.
- Tyrosine kinase inhibitor: A type of drug that blocks the action of enzymes known as tyrosine kinases, which can promote the growth of cancer cells.
- BCR-ABL: A fusion gene that is formed as a result of the Philadelphia chromosome mutation, which is associated with chronic myeloid leukemia.
- Novartis: A multinational pharmaceutical company based in Switzerland.
Side Effects
Like all medications, Asciminib can cause side effects. Common side effects include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include heart problems, liver problems, and bleeding.
See Also
External links
- Medical encyclopedia article on Asciminib
- Wikipedia's article - Asciminib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski